Gt Biopharma, Inc. · NASDAQ:GTBP
Gt Biopharma — Investor Presentation (September 2021)
23 slides from Gt Biopharma's investor presentation, Sep 13, 2021
Slide 1: GT Biopharma: Target Directed NK Cell Immunotherapy
GT BIOPHARMA Target Directed NK Cell Immunotherapy NASDAQ: GTBP —_—SSEEEEEEEEEET 10 September 2021 Non-Confidential
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This presentation includes statements that are, or may be deemed, “forward-looking statements.” In some cases, you can identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may
Slide 3: GT Biopharma Recent Major Milestones
GT BIOPHARMA RECENT MAJOR MILESTONES March 2019 February 2020 October 2019 October 2020 HIV TrKE® data demonstrates Results of B7H3 targets NK cel Killing muftiple cancers February 2021 NASDAQ Listing Raise 23.7 MM Public Offering June 2021 GTB Added to RUSSELL 2000 July 2021 September 2021 Non-Conf
Slide 4: Company Focus — Harnessing Natural Killer Cells to Fight Cancer
Company Focus — HARNESSING NATURAL KILLER CELLS To FiGHT CANCER Source: Levy R. Paths of Progress 2019, Natural Killer Cells: defense may play a newfound role in cancer care; accessed: httoss//wunw. dana farbe rom foid ex Restore patient’s exhausted/inhibited endogenous NK cell population to again r
Slide 5: What Is a TriKE Therapeutic?
WHAT Is A TRIKE® THERAPEUTIC? » —NK Cell cp16 + anti-cb16 — 1L-15 Cancer Cell Binder Cancer Cell Target — Cancer Cells Key Therapeutic Features: Target-directed ADCC killing. Integrated cytokine support within the tumor micro-environment (TME). Simultaneous NK cell ADCC activation, proliferation and
Slide 6: TriKE Product Candidate Pipeline
TRIKE® PRODUCT CANDIDATE PIPELINE Approach Stage Pre-Clinical GMP Manufacturing Phase 1 Leukemia — AML, MDS, ‘ere-ss0 ‘Monotherapy Se Camelid Combination with Chemotherapy GTB-4550 ‘Monotherapy & PD-LL fee Solid Tumor Camelid ‘Combination GTB-5550 ‘Monotherapy & B7H3 is al Tumor Camelid Combination
Slide 7: TriKE Directed NK Cell Serial Killing of AML Cancer Cells
TRIKE® DIRECTED NK CELL SERIAL KILLING OF AML CANCER CELLS ¢ Integrated CD16 and IL-15 in TriKE drives: > NK cell ADCC activation for enhanced serial killing of cancer cells > NK cell proliferation > NK cell persistence ¢ TrikE minimizes toxicities such as cytokine release syndrome (CRS) resulting f
Slide 8: GTB-3550 TriKE Product Candidate
GTB-3550 TRIKE® PRODUCT CANDIDATE source: Pr. 3 Bernard/CNRi/Science Source 7 First-in-Class immune oncology therapy. Target-directed NK cell ADCC killing of CD33+ hematological cancers. Incorporates IL-15 within therapeutic for enhanced NK cell proliferation and persistence. Currently being evaluat
Slide 9: TriKE GTB-3550 Phase 1 Study Design
TRIKE® GTB-3550 PHASE 1 Stupy DESIGN Phase 1 eae 2 Safety and Dose Finding” Tn “oe Sereening/ ; ‘enrollment: -RUR AML "Bionoeay_ 2) -HRMSD ‘Safety Expansion 20% cDa3+ “Advanced ia Disease Re-assessment ‘argetcatts, | SP} Systemic = Soy on) | 150 poaitay sessne with no SOC =) bos et rentment Seam me
Slide 10: GTB-3550 TriKE First-in-Human Clinical Trial Interim Results
GTB-3550 TRIKE® FIRST-IN-HUMAN CLINICAL TRIAL INTERIM RESULTS Patient | _Dose Level Disease and Prot THeatment History Disease Characteristics Before GTB 3550Therapy | Disease Characteristics After GTB 3550 Therapy 7 Smce/ke/dey [Therapy rented AML Faled STinesof induction therapy [etitarty: 10% eta
Slide 11: GTB-3550 TriKE Is Well Tolerated by Subjects Enrolled
GTB-3550 TRIKE® Is WELL TOLERATED BY SUBJECTS ENROLLED Panel A: Dose Equivalent of GTB-3550 and Systemic Maximum Therapeutic Dose of IL-15 PER MOLE BASIS Dose of GTB-3550 (g/kg) | Fold Higher than MTD rhil-15 5 0.54 10 1.08 25 2.69 50 5.38 100 10.75 150 16.13 Panel C: Heart Rate = F 3 3 Panel B: Sys
Slide 12: GTB-3550 TriKE First-in-Human Clinical Trial Interim Results
GTB-3550 TRIKE® FIRST-IN-HUMAN CLINICAL TRIAL INTERIM RESULTS TriKE® activates endogenous NK cells in the periphery and they egress into tissues Panel A: Increase in NK cell activation upon administration of GTB-3550. Panel B: Increase in absolute number of NK cells during treatment. SsODES+ NK Abso
Slide 13: GTB-3550 TriKE Clinical Trial Immune Monitoring Results
GTB-3550 TRIKE® CLINICAL TRIAL IMMUNE MONITORING RESULTS No Loss of CD16 During GTB-3550 Therapy Separates cDSébright and CDS6dim CD56 GTB-3550 Therapy Ends Day 19 Data from Subject #7 treated with 50 ug/kg/day Non-Confidential 3
Slide 14: GTB-3550 TriKE First-in-Human Clinical Trial Interim Results
GTB-3550 TRIKE® FIRST-IN-HUMAN CLINICAL TRIAL INTERIM RESULTS * GTB-3550 TriKE induces reproducible NK cell proliferation in all subjects at all dose levels evaluated with no clinically significant toxicity. No CRS resulting from hyperactivation of subject’s T-cell population at doses 5 — 100 pg/kg/
Slide 15: Camelid Antibodies — Second Generation TriKE
CAMELID ANTIBODIES — SECOND GENERATION TRIKE® + Camelid antibodies are antibodies from the Camelidae family of mammals that include llamas, camels, and alpacas. art Cha ory ree + Camelid antibody is made up of only 2 heavy chains. This is known as heavy chain IgG (hclgG). While these antibodies do n
Slide 16: Second Generation TriKE (Camelid) Improves NK Function
SECOND GENERATION TRIKE® (CAMELID) IMPROVES NK FUNCTION CD 33+ HL60 Targets 2 S —e scFv16-m15-33 —= cam16-wt15-33 FS 2 Ss 3 %CD107a+ NK Cells % 8 eo s 01 1 10 100 Concentration (nM) Source: Felices M etal. Cancer Immunol Res 2020 Sep; 8(9): 11391149 8 —> scFv16-m15-33 = cam16-wt15-33 %IFNg+ NK Cells
Slide 17: Second Generation TriKE (Camelid) Superior In-Vivo
SECOND GENERATION TRIKE® (CAMELID) SUPERIOR IN-Vivo NT, seF¥v16-m15-23, oF camt6-WttS-33 (IP) acc a ~% peoea bugga ] I ] ] o 7 14 21 BL (umr oad) Wieas Harve NK col pombersh orsxt0® VINK Celts ~ 1x10" Q v1 a] & 28 ee 8 ce 4 os Ss = 3 LE <= 4 Ze ro é & Source: Felices M etal. Cancer Immunol Res 2020
Slide 18: Second Generation TriKE (Camelid) Highly Effective Against HER2+ Tumors
SECOND GENERATION TRIKE® (CAMELID) HIGHLY EFFECTIVE AGAINST HER2+ TUMORS A No Treatment Antibody Control was CAMIGISHER2 3% Spherod Size SPPTTOT SSS ‘Spheroid intensity Target Cal te ntensty © pas ‘Normsina % By Tine Pot ‘Source: Valera DA etal. Cancer 2021 Aug 8; 13(26):3994 Non-Confidential 18
Slide 19: Pipeline TriKE B7H3: Multi-Cancer Strategy
PIPELINE TRIKE® B7H3: MUuLTI-CANCER STRATEGY Day 21 After MA-148 Tumor Implant MA148 2 - nee see 8 St oe Tumor 4 6 ta 5 NK + a2 115 oO x > 2 £ £ $ & af, NK + “ey pete TriKE® B7H3 = = Dosing: 1g: 5x/week (MTWThF) & a Schedule: 3 weeks Significant killing of MA148 Ovarian Cancer by TriKE® B7H3 Source:
Slide 20: Multi-Layered Patent Strategy
MuLTI-LAYERED PATENT STRATEGY TriKE® Method of Use Patent Claims + Methods of use claims highlighting coverage for oncology and infectious disease therapeutic applications. TrikKE® Composition of Matter Patent Claims + Composition of matter claims covering DNA and amino acid sequences for all TriKE™
Slide 21: Competition
COMPETITION TriKE® Competitive Advantages > The anti-CD16 component of the TriKE binds FcRyIlI at high affinity compared to ADCC mediated strategies that bind at low affinity. > CD16 +/- other receptor engagement does not result in proliferation of T-cells contributing to CRS. > IL-15 provides NK ce
Slide 22: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM PROVEN RECORD IN BIOTECH, PHARMA, PRODUCT DEVELOPMENT, FINANCING —a Anthony Cataldo Gregory Berk, MD Chairman and Chief Executive Oficer President RED ond Chie! Medical Officer TOVANCE caevere CD) verastem inteltixine Drees Gavin Choy, PharmD, MBA (Ciel, Cinical Developme
Slide 23: GT Biopharma
GT BIOPHARMA Target Directed NK Cell Immunotherapy NASDAQ: GTBP —_—SSEEEEEEEEEET 10 September 2021 Non-Confidential
GT Biopharma — Investor Presentation (September 2021) on 6ix